Top Beverage Stocks For 2016

It’s been a long decade for Yahoo (Nasdaq: YHOO). The search and tech company has seen its stock rise just 10% over the past 10 years.

This comes after years of battling activist investors, a carousel of CEOs, and a declining business. The saving grace has been Alibaba (Nasdaq: BABA), where Yahoo has a 15% stake in the company. The success of Alibaba has helped overshadow Yahoo’s own problems.

However, a perfect storm has been brewing at Yahoo. The company announced plans to spin-off its stake in Alibaba in early 2015. Yahoo invested in Alibaba back in 2005 and was finally looking to unlock value from the appreciation. However, Yahoo abandoned the plan, because the spinoff won’t be tax-free as initially anticipated — and the tax bill would be sizable given the growth in Alibaba. Instead, Yahoo decided to try and spinoff its own core business, including the search business and websites such as Yahoo Mail and Yahoo Finance, which would still be a taxable transaction. Then, just last month, Yahoo also said it’s willing to sell the core business. There are now tensions over the future of the company and whether Marissa Mayer is the best CEO for the job.

Top Beverage Stocks For 2016: Extra Space Storage Inc(EXR)

 

Extra Space Storage, Inc. operates as a real estate investment trust (REIT) in the United States. It engages in property management and development activities that include acquiring, managing, developing, and selling, as well as the rental of self-storage facilities. As of December 31, 2006, Extra Space Storage owned interests in 567 properties located in 32 states and Washington, D.C., as well as managed 74 properties owned by franchisees or third parties. As a REIT, the company would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 1977 and is based in Salt Lake City, Utah.

Advisors’ Opinion:

  • [By Shauna O’Brien]

    On Tuesday, Goldman Sachs announced that it has removed Extra Space Storage, Inc. (EXR) from its Conviction Buy List.

    The firm has maintained a “Buy” rating on EXR, and has lowered the company’s price target from $51 to $50. This price target suggests a 12% upside from the stock’s current price of $43.94.

    Analyst Andrew Rosivach commented: “We think the stock is inexpensive on forward 2018E AFFO, but the higher 2014E multiple may require the stock to consolidate.”

    Extra Space Storage shares were down 21 cents, or 0.47%, during Tuesday morning trading. The stock is up 21% YTD.

Top Beverage Stocks For 2016: BioMarin Pharmaceutical Inc.(BMRN)

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. The company?s commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis (MPS) VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It develops GALNS, an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-673, a Phase I/II clinical trial product for the treatment of cancer; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of Kuvan and other products containing 6R-BH4 and PEG-PAL for PKU. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in Novato, California.

Advisors’ Opinion:

  • [By Nick Taborek]

    BioMarin Pharmaceutical Inc. (BMRN) rallied 3.2 percent to $79.99. Roche Holding AG, the worlds biggest maker of cancer drugs, is lining up as much as $15 billion in debt financing to buy Novato, California-based BioMarin, DealReporter reported, citing people familiar with the situation.

  • [By Ben Levisohn]

    SRPT’s dystrophin argument strongly challenged and largely invalidated by the FDA. Recall, the panelists were very critical of dystrophin data for BioMarin Pharmaceutical (BMRN), and we expect a similar level of scrutiny. The FDA points out two major concerns with Sareptas method of quantifying dystrophin expression: 1) reconciling the low correlation between Western blot vs. immunofluroesscence, and 2) overexaggeration of the data. To the first point, not only was the correlation between the two methods not strong, when considering Western blot as a more relevant and reliable quantitative measurement for dystrophin expression, FDA sees the resulting 0.9% (of normal) after 3.5 years as disappointing. To the latter point, the applicants suggestion of an 11.6-fold increase in de novo dystrophin production assumes a baseline of 0.08% dystrophin level, which is below the instruments detection level of 0.25%.

  • [By Monica Gerson]

    BioMarin Pharmaceutical (NASDAQ: BMRN) shares moved up 1.48% to $78.64. The volume of BioMarin Pharmaceutical shares traded was 966% higher than normal. BioMarin shares jumped on Roche Holding (OTC: RHHBY) takeover report..

Top US Companies To Watch For 2016: Prestige Brand Holdings Inc.(PBH)

Prestige Brands Holdings, Inc., together with its subsidiaries, engages in marketing, selling, and distributing over-the-counter healthcare and household cleaning products primarily in North America. The company?s Over-The-Counter Healthcare segment offers a portfolio of OTC products under nine core OTC brands, including Chloraseptic sore throat remedies, Clear Eyes eye drops, Compound W wart removers, Dramamine motion sickness products, Efferdent and Effergrip denture products, Little Remedies pediatric healthcare products, Luden’s cough drops, PediaCare pediatric healthcare products, and The Doctor?s brand of oral care products. This segment also provides other significant brands that include Dermoplast first-aid products, Murine eye and ear care products, NasalCrom allergy relief product, New-Skin liquid bandage, and Wartner wart removers. Its Household Cleaning segment markets household cleaning products, such as abrasive and non-abrasive tub and tile cleaner, scrubb i ng pads and sponges, dilutables, anti-bacterial hard surface spray for counter tops, and glass cleaners under the Comet, Chore Boy, and Spic and Span brands. Prestige Brands Holdings distributes its products through various retail channels, including drug, food, dollar, and club stores, as well as supermarkets and mass merchandisers. The company was founded in 1996 and is headquartered in Irvington, New York.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Castor believes the cash has disappeared into working capital, which has grown from 23% to more than 50% since 2008. Comparable company PrestigeBrand (PBH) uses 11%; Unilever(UL) and Colgate-Palmolive(CL) far less.